Zongertinib (BI.1810631) Phase I Study in Advanced Solid Tumors with HER2 Aberrations focusing on NSCLC. The trial involves dose escalation and expansion, testing different doses in cohorts with varied HER2 mutations. Primary endpoints include MTD, OR, and DLTs.

2 views • 14 slides

HER2 activation plays a crucial role in promoting tumor proliferation and survival in NSCLC. Driven by oncogenic downstream signaling pathways, HER2 overexpression and gene amplification lead to the formation of heterodimers and activation of key signaling cascades. Additionally, HER2 mutations are

0 views • 36 slides

Study on Zongertinib, a HER2 tyrosine kinase inhibitor, in patients with HER2 aberration-positive solid tumors. The trial involves multiple centers worldwide and aims to evaluate the efficacy of Zongertinib in treating various cancers harboring HER2 mutations. Financial disclosures of lead investiga

1 views • 13 slides

Trastuzumab Deruxtecan (T-DXd) 100 mg, available through Impomed Healthcare in India, represents a breakthrough in the treatment of HER2-positive cancers. This innovative antibody-drug Trastuzumab Deruxtecan 100 mg in India conjugate offers precise targeting of cancer cells while minimizing damage t

0 views • 10 slides

This document explores Tucatinib 150 mg, a cutting-edge tyrosine kinase inhibitor available in India for treating HER2-positive breast cancer. It covers the medicines benefits, potential side effects, and availability, along with expert insights from

0 views • 11 slides

This event on March 2, 2021, gathered experts in the field to discuss the optimal management of HER2-positive breast cancer. The agenda covered topics such as early breast cancer management, treatment sequencing for metastatic disease, and real-life case scenarios. Speakers shared insights on COVID-

0 views • 50 slides

Ongoing breast cancer research projects focusing on biomarker validation, new team initiatives, and imaging advancements are detailed. Notable efforts include the investigation of triple-negative breast cancer markers, benign breast disease progression markers, ER+ and HER2+ biomarkers, and breast c

0 views • 9 slides

This PDF offers an in-depth overview of Trastuzumab Deruxtecan, a targeted therapy for HER2-positive cancers. It discusses its uses, benefits, side effects, and Trastuzumab Deruxtecan 100 mg availability in India, highlighting its potential to improve patient outcomes and access to advanced cancer t

0 views • 11 slides

Explore the selection and sequence of therapy for ER-positive, HER2-negative metastatic breast cancer, along with novel agents and strategies under evaluation. Learn about cases of postmenopausal women with metastatic breast cancer, CDK4/6 inhibitors, and the impact of targeted therapies on patient

0 views • 23 slides